For the past 10 years, Ethismos scientists and researchers have been dedicated to studying, defining and harnessing the potent effects and the promising therapeutic indications of our core molecules to treat some of the most challenging conditions..... addiction, depression and chronic pain.
The core of our therapies is a small molecule called amitifadine. This molecule is known as a serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI) or “triple uptake inhibitor” because amitifadine modulates the amounts of these three neurotransmitters in the brain. These three neurotransmitters are important in many conditions and disorders including: addiction, depression, impulse-control, pain, and obesity.
Amitifadine is well known and has been extensively studied for several important indications. The Ethismos team has accumulated over a decade of research and development on amitifadine -and has conducted several human trials and amassed corresponding data to demonstrate safety and efficacy. A rigorous, comprehensive preclinical testing program necessary for U.S. New Drug Application (NDA) is very advanced, and the Ethismos team and collaborating partners are preparing for FDA Phase 2b clinical trials for three unique indications associated with opioids prescribed for chronic pain, smoking cessation and treatment resistant depression, with ongoing research in several other indications and therapies with promising and compelling results.
The Ethismos team and our collaborating partners are among the best and brightest scientist, researchers and clinicians in the world. We are driven by a common passion - to discover, develop and advance therapies to help people return to lives without substance abuse.